CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--VIASYS Healthcare Inc. (NYSE:VAS), through its Respiratory Care division, announced today that it has received FDA 510(k) pre-market notification clearance for a new Nasal CPAP option for the AVEA® ventilator. The AVEA is an advanced generation integrated life support system designed to meet the needs of all neonatal, pediatric and adult patients. This new option will allow the AVEA to provide non-invasive CPAP to neonatal patients and is designed to work with most common nasal prongs.
